Development and feasibility of randomized trial to reduce urinary bisphenols in women with obesity

Todd Hagobian,Alyssa Bird,Suzanne Phelan,Megan Guy,Adrian Mercado,Zoe Delli-Bovi

doi:10.1186/s40814-020-00744-5

Todd Hagobian, Alyssa Bird + Show 4 more

Open Access

https://doi.org/10.1186/s40814-020-00744-5

Copy DOI

Abstract

BackgroundBisphenol exposure is widespread and correlated with diabetes and cardiovascular disease. Previous intervention studies have successfully lowered bisphenol exposure among women of normal weight. The primary objective of this study was to develop and test the feasibility of a 3-week behavioral change intervention, rooted in social cognitive theory, to lower a broad range of bisphenols (BPA, BPS, and BPF) in women with obesity.MethodsThirty women with obesity (31.1 ± 5.6 kg/m2, 21.1 ± 3.1 years) were randomly assigned to an intervention or control. The intervention included weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Fasting urinary bisphenols, creatinine, and weight were assessed at study entry and after 3 weeks.ResultsThe intervention was evaluated as feasible (100% of enrollment and recruitment, 96% of retention and attendance at lesson plan visits, and 96% of a collection of urine samples). Adherence to the intervention was estimated based on completion of self-monitoring records; the number of daily records completed was 7.7 ± 1.3 (mean ± SD) after week 1, 7.1 ± 1.5 after week 2, and 4.4 ± 0.9 after week 3. In secondary analysis, there was a significant treatment × time effect on creatinine-corrected urinary BPS (− 1.42 μg/g creatinine in the intervention vs. − 0.09 μg/g creatinine in the control group).ConclusionIn women with obesity, the 3-week intervention was considered feasible with promising preliminary results of decreasing BPS concentrations. These data warrant future large-scale clinical trial interventions to reduce bisphenol exposure and determine whether reductions in bisphenols positively impact diabetes and cardiovascular disease risk markers. This study was retroactively registered at ClinicalTrial.gov Identifier NCT03440307.

Highlights

Bisphenol exposure is widespread and correlated with diabetes and cardiovascular disease
Non-persistent endocrine-disrupting chemicals, including bisphenol A (BPA) and analogs bisphenol S (BPS) and bisphenol F (BPF), are compounds routinely used in the production of plastics, appearing in the lining of food and beverage containers and several other products commonly used by consumers [1,2,3]
The human exposure to bisphenols is extensive; an analysis of the National Health and Nutrition Examination Survey (NHANES) data showed that 93% of the US population had detectable levels of BPA [4]

Summary

Introduction

Bisphenol exposure is widespread and correlated with diabetes and cardiovascular disease. We noted a small, albeit significant difference in a 3-week weight (P = 0.03; − 0.28 kg weight loss vs + 1.65 kg weight gain) in intervention vs control participants, respectively, in our sample of normal-weight women; this might have been due to self-monitoring of caloric intake that occurred in the intervention group. These and other [16] data suggest that short-term interventions may successfully reduce BPA exposure in women with normal weight. Efficacious interventions to reduce bisphenol exposure in women with obesity are needed

Objectives

Methods

Results

Discussion

Conclusion